- In February 2023, Medtronic announced the relaunch of its first-of-its-kind transcatheter pulmonary valve replacement system, designed for patients with congenital heart disease. This minimally invasive procedure replaces the pulmonary valve using a catheter, offering an alternative to traditional open-heart surgery. The system reduces recovery time, lowers the risk of complications, and shortens hospital stays. It is especially beneficial for patients who previously underwent heart surgery and now require a pulmonary valve replacement. The relaunch aims to improve long-term patient outcomes, enhance quality of life, and provide a less invasive, more accessible solution for those with congenital heart conditions.
- In September 2024, Edwards Lifesciences announced the launch of the SAPIEN 3 valve with the Alterra Present in Europe for transcatheter pulmonic valve implantation. This ground-breaking solution is designed to treat patients with pulmonary valve dysfunction, particularly those with congenital heart disease. The system combines the SAPIEN 3 valve, known for its durability and performance, with the Alterra Present, which provides a scaffold to stabilize the valve. This new combination enhances procedural success, reduces the risk of complications, and improves long-term patient outcomes. The innovation aims to offer a safer, minimally invasive treatment option, reducing recovery time and hospital stays for patients.
